Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Shopify Inc. (SHOP) vs Viatris Inc (VTRS) Price & Performance

Shopify Inc.Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Shopify Inc. vs Viatris Inc — how do they compare? Shopify Inc. trades at $149.44 (market cap $196.35B), while Viatris Inc trades at $16.18 (market cap $18.69B). The key difference: Shopify Inc. is far larger — about 10.5× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.

SHOPVTRS
Market Cap
$196.35B$18.69B
Sector
TechnologyHealth
52-Week High
$179.01$17.86
52-Week Low
$95.40$9.49
Enterprise Value
$191.59B$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Shopify Inc.

Shopify (SHOP) trades at $149.19, down 3.86% over 24 hours, but maintains a bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates with 30%+ GMV growth, while revenue reached $11.56 billion in 2025. Analyst sentiment is overwhelmingly positive, with 65.6% recommending Buy and a consensus price target of $166.39.

Outlook remains favorable driven by AI commerce integration and expanding payments, but high valuation multiples (P/E 103.11) pose risks if growth slows. Key supports include operational cash flow growth to $2.03 billion in 2025, though competition and macroeconomic pressures require monitoring for sustained upside.

Viatris Inc

Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.

Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Shopify Inc.

Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.

Read more on SHOP

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS